[a number of pharmaceutical companies issued share buyback plans industry insiders: the current pharmaceutical industry valuation is low] FIFA News Agency, May 17, recently, a number of pharmaceutical companies issued share buyback plans. Hengrui Pharmaceutical plans to buy back shares with 600 million yuan to 1.2 billion yuan, Watson Biological plans to buy back shares with no more than 200 million yuan, and Yabao Pharmaceutical Company plans to buy back shares with 150 million yuan to 300 million yuan. Industry insiders believe that the current valuation of the pharmaceutical industry is low. Share buyback helps to boost investor confidence, promote the establishment of a long-term incentive mechanism, and improve the quality of listed companies. (China Securities News)